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udden Death in Patients
ithout Structural Heart Disease
ric F. D. Wever, MD, PHD,*† Etienne O. Robles de Medina, MD, PHD, FACC‡
trecht and Nieuwegein, the Netherlands
Sudden unexpected cardiac death generally occurs in persons with known or previously
unrecognized heart disease. However, it has become evident that it occurs often enough in
patients without any identifiable structural abnormality to warrant the cardiologist’s attention.
Mostly, it concerns young, active, and otherwise healthy individuals. This paper focuses on
various categories of patients with life-threatening events considered to have occurred on a
solely “electrical” basis. Currently, several entities are recognized with distinct electrophysi-
ological abnormalities, including Wolff-Parkinson-White syndrome, long QT syndrome, the
Brugada syndrome, short-coupled torsade de pointes, and catecholamine-induced polymor-
phic ventricular tachyarrhythmia. The remaining patients without such distinct abnormalities
are categorized as having idiopathic ventricular fibrillation. Although mechanical cardiac
function may seem normal, such patients might have certain discrete anatomic abnormalities,
unidentifiable with current investigational tools. Possibly in the future, with development of
newer and more sophisticated tools (magnetic resonance imaging, positron emission tomog-
raphy, genetic testing), some or all cases of idiopathic ventricular fibrillation must be redefined
as having specific genetic and/or anatomic bases. All patients successfully resuscitated from
cardiac arrest due to ventricular tachyarrhythmia without clear precipitating factors (acute
myocardial infarction, severe electrolyte or metabolic disturbances) are at high risk of
recurrences. Long-term prophylactic therapy is indicated. Contrasting with older belief,
survivors of idiopathic ventricular fibrillation are now also considered high-risk patients. The
implantable cardioverter-defibrillator appears to be the safest and most effective
therapy. (J Am Coll Cardiol 2004;43:1137–44) © 2004 by the American College of
Cardiology Foundationl
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oudden cardiac death (SCD) is defined as unexpected
atural death from a cardiac cause occurring within a
hort time (generally within 1 h of onset of symptoms) in
ersons without prior conditions that would appear fatal
1,2). Most victims (90%) have previously known or
nrecognized cardiac abnormality (1–5). At autopsy,
oronary artery disease, hypertrophic cardiomyopathy
with or without obstruction), and valvular aortic stenosis
re the most common causes. Small percentages show no
tructural abnormalities. Evidently, however, SCD occurs
ften enough in patients with apparently normal hearts to
arrant cardiologic attention. Sudden cardiac death has a
imodal incidence peaking between birth and six months
sudden infant death syndrome), and between 45 and 75
ears of age, due to development of coronary artery
isease. Patients without underlying disease, however, are
sually strikingly younger (40 years old) (1). Despite
etter pathophysiologic understanding and development
f refined diagnostics and treatment modes, SCD re-
ains a major issue. Annual numbers are 300,000 to
00,000 (U.S.) (2) and 30,000 to 40,000 (the Nether-
From the *Department of Cardiology, Heart Lung Center, Utrecht, the Nether-
ands; †St. Antonius Hospital, Nieuwegein, The Netherlands; and ‡University
edical Center Utrecht, Utrecht, the Netherlands. Bernard J. Gersh, MD, acted as
he guest editor for this paper.
Manuscript received December 4, 2002; revised manuscript received October 7,
t003, accepted October 30, 2003.ands). Sudden cardiac death is mostly (80%) due to
entricular fibrillation (VF) or rapid ventricular tachycar-
ia (VT) (1). The chance of reaching the hospital after
uccessful resuscitation is small (30%); the chance of
eaving the hospital alive even smaller (6). Epidemiologic
tudies revealed that the overall group of cardiac arrest
VT/VF) survivors are at major risk of recurrent life-
hreatening events (25% to 40% within two years) if no or
nly empiric treatment is offered (7). Current agreement
s that such patients should be analyzed in-hospital with
xtensive (non)invasive procedures to detect causes and
echanisms of death and to assess proper treatment. In
atients without demonstrable underlying disease, certain
lectrical conditions are assumed to have led at some
oint to electrical derangement. In some patients, these
re attributable to distinct primary electrophysiological
ntities; in others, they remain unidentified. It should be
ealized that, although mechanical cardiac function may
e (grossly) normal, patients might have discrete abnor-
alities, which are currently unidentifiable. This paper
ocuses on categories of patients suffering a life-
hreatening event (especially VF), in whom the cause is
onsidered to have a solely “electrical” basis. As idio-
athic VF can generally be diagnosed only after a battery
f investigations, we will start with a survey of etiologies
hat should be considered first.
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onditions that may be associated with or may mimic SCD
re summarized in Table 1 (8–22). Most VT/VF patients
80%) have atherosclerotic coronary artery disease; 50%
ave remote myocardial infarction. Ventricular tachycardia/
entricular fibrillation may also develop during acute coro-
ary syndromes and coronary artery spasm (23). Cardiomy-
pathies form the second largest group of etiologies. Other
onditions are rare. Genetic screening may be necessary for
Abbreviations and Acronyms
AV  atrioventricular
EPS  electrophysiologic study
ICD  implantable cardioverter-defibrillator
IVF-US  Idiopathic Ventricular Fibrillation Registry
of the United States of America
LQTS  long QT syndrome(s)
SCD  sudden cardiac death
U-CARE  Unexplained Cardiac Arrest Registry Europe
VF  ventricular fibrillation
VT  ventricular tachycardia
WPW  Wolff-Parkinson-White
able 1. Abnormalities Associated With Sudden Death
oronary artery abnormalities
Atherosclerotic
Nonatherosclerotic (arteritis, embolism, dissection, congenital
malformations, anomalous origin of left coronary artery from
pulmonary artery or right or noncoronary aortic sinus of Valsalva
[artery passing between the aortic and pulmonary artery roots]) (8)
yocardial abnormalities
Hypertrophic cardiomyopathy (9,10)
Idiopathic dilated cardiomyopathy (11)
Arrhythmogenic right ventricular dysplasia (congenital right
ventricular cardiomyopathy (12,13)
Myocarditis (14)
Sarcoidosis or other infiltrative diseases
Left ventricular hypertrophy
Valvular and congenital heart disease
ther conditions
Aortic dissection
Acute cardiac tamponade
Rapid exsanguination
Pheochromocytoma
Subarachnoid hemorrhage
Cafe´ coronary (15) (acute glottis obstruction by food)
Holiday heart syndrome (16)
Acute alcoholic states (17)
Massive pulmonary embolism
Severe asthmatic attacks (18)
Peripartum air or amnionic fluid embolism (19)
roarrhythmic effects*
Antiarrhythmic drugs (20,21)
Psychotropic agents, phenothiazines, antihistamines, antibiotics,
gastrointestinal drugs
Anorexia nervosa
Toxic substances
Electrolyte abnormalities (22)
Often (but not always) associated with QT prolongation (acquired long QT). Classic
roarrhythmia usually occurs within days after initiation of treatment but may extendaver one year of exposure (21).utations of beta-myosin heavy chain, cardiac troponin T,
ardiac alpha-tropomyosin, and myosin-binding protein C
enes (hypertrophic cardiomyopathy) (10) or defects on
hromosomes 1 and 14 q23-q24 (arrhythmogenic right
entricular dysplasia) (12). Arrhythmogenic right ventricu-
ar dysplasia occurs in some 30% as familial disorder with an
utosomal dominant inheritance pattern.
RIMARY ELECTROPHYSIOLOGIC ABNORMALITIES
n some VT/VF patients, no underlying heart disease is
emonstrable. Currently, several entities with distinct elec-
rophysiologic abnormalities are recognized. Wolff-
arkinson-White (WPW) syndrome (24) and the congen-
tal long QT syndromes (LQTS) (25) are the oldest
xamples. Sudden cardiac death may also be caused by
ransient and correctable causes (electrolyte disturbances,
etabolic disturbances, and intoxications/drugs). Such ab-
ormalities are usually associated with QT prolongation on
he electrocardiogram. Of note is that low potassium levels
ay occur due to acute major stress (e.g., resuscitations).
evels of 2.5 to 3.0 mmol/l are not uncommon in such
ituations. Therefore, it may be difficult to ascribe the
ccurrence of VF to hypokalemia, unless there is a history of
lectrolyte imbalance during steady state, use of medica-
ion(s), or diets known to deplete potassium. Hypomag-
esemia may be suspected in cases of malnutrition, gastro-
ntestinal, renal or endocrine disorders, or alcoholism. In
ome patients, neither underlying disease nor distinct elec-
rophysiologic abnormalities or electrolyte or metabolic
erangement may be demonstrable. This condition is called
diopathic VF.
PW SYNDROME
olff-Parkinson-White syndrome is caused by accessory
trioventricular (AV) connections bypassing the AV node
nd His bundle. Although rarely associated with other
ongenital cardiac anomalies (e.g., M. Ebstein), it is usually
n isolated abnormality. With a short anterograde effective
efractory period of the accessory pathway, the ventricular
esponse during atrial fibrillation may be (extremely) rapid
ith the risk of deterioration into VF (26). Anterograde
ffective refractory periods 250 ms, best identified by
easuring the shortest interval between preexcited QRS
omplexes during atrial fibrillation, are considered unfavor-
ble in symptomatic patients (26,27). The WPW patients
ave an SCD risk of 1/1,000 patient-years follow-up (2).
ost SCD survivors have experienced arrhythmias before
he event but, in up to 10%, SCD may occur as first
anifestation (28). In many cases, the resting electrocardio-
ram (ECG) shows preexcitation. However, independent of
heir anterograde conduction characteristics, left-sided ac-
essory pathways may not be apparent on the surface ECG.
herefore, an electrophysiologic study (EPS) is necessary to
dentify the existence of anterograde preexcitation and to
ssess the possible associated risk.
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April 7, 2004:1137–44 VF Without Structural Heart Diseasereatment. For symptomatic patients, catheter ablation is
ow first-choice therapy with 95% effectiveness. If inef-
ective, antiarrhythmic drugs prolonging the anterograde
ffective refractory period of the accessory pathway or
ardiac surgery are alternatives. Consensus remains that in
symptomatic patients catheter ablation is not indicated
29). As SCD may be the first manifestation (28), and in
iew of current high success rates of catheter ablation, this
pinion might need reconsideration.
ONGENITAL LONG QT SYNDROMES (LQTS)
ongenital LQTS (25,30) have long been considered idio-
athic. At present, LQTS have been identified as geneti-
ally determined heterogeneous diseases affecting the potas-
ium or sodium channels, and causing abnormally
rolonged repolarization. This leads to QT prolongation on
he ECG; the traditional criterion being a QT corrected for
eart rate 0.44 s for men and 0.46 s for women (3,30).
ther ECG criteria are dispersion of (corrected) QT,
bnormal STT wave contours, (macroscopic) T wave alter-
ans, lower than normal heart rates, and the occurrence of
inus node pauses (30,31). When marked QT prolongation
s present, the diagnosis is straightforward. For less clear
ases, a scoring system has been introduced in which other
haracteristics (T-wave alterations, clinical phenotype, and
amily history) are taken into account (30). In the future,
enetic screening will undoubtedly allow for more accurate
stablishment of the diagnosis.
Long QT syndrome patients carry a relatively high risk of
evelopment of polymorphic VTs called “torsades de
ointes.” These are typical, rapid, polymorphic, but still
rganized VTs with progressive changes in morphology,
mplitude, and polarity of the QRS complexes twisting
round the isoelectric line. The long coupling interval (600
o 800 ms) of the initial complex is typical (32). Torsades de
ointes are triggered by early afterdepolarizations, often (but
ot always) occurring in the setting of high adrenergic
ctivity (physical or emotional stress, sudden arousal) (33).
lthough frequently causing loss of consciousness, they are
ften self-terminating, but sometimes deteriorate into VF.
he clinical picture is sometimes mistaken for epileptic
eizures.
Two major clinical LQTS have been characterized based
n genetic transmission pattern: the more common autoso-
al dominant form with a pure cardiac phenotype,
omano-Ward syndrome (34,35), and the rare autosomal
ecessive form with coexisting congenital deafness, Jervell-
ange-Nielsen syndrome (36).
enetic background. Genetic research has recently iden-
ified six loci and five genes associated with Romano-Ward
yndrome. They are located on chromosomes 3, 4, 7, 11,
nd 21 (37). KvLQT1 (LQT1, chromosome 11), HERG
LQT2, chromosome 7), KCNE1 and KCNE2 (LQT5 and
QT6, respectively, chromosome 21) encode potassium-
hannel subunits, while SCN5A (LQT3, chromosome 3) mncodes the cardiac sodium-channel. Homozygous muta-
ions in KvLQT1 and KCNE1 are associated with the
ervell-Lange-Nielsen syndrome (37). For LQT4, the gene
t chromosome 4 has not yet been identified. There are
amilies with LQTS not linked to any of these five loci. So
here must be other genes encoding LQTS. LQT1 and
QT2 are the most frequently encountered forms; LQT3,
QT4, and LQT5 are rare.
The incidence of cardiac events is higher in LQT1 and
QT2 than in LQT3 patients; however, the lethality of
ardiac events is higher for LQT3 than for LQT1 and LQT2
atients (38). In LQT1 patients, torsades de pointes are
specially triggered by physical stress, particularly swimming
nd diving; in LQT2 patients, by sudden arousal (33). In
QT3 patients, arrhythmias predominantly occur at rest or
uring sleep (38,39).
udden infant death syndrome. This is a leading cause of
eath in the first year of life. The incidence peaks between
and 12 weeks of age. The etiology is still unknown,
lthough recent data suggest that it may be due to a subtype
f LQT3 with low penetrance (40). Indeed, these entities
ave certain clinical features in common, such as the
ccurrence of SCD at rest or during sleep.
reatment. For most patients with LQTS (LQT1, LQT2,
QT4, LQT5, and the Jervell-Lange-Nielsen syndrome),
eta-blocker therapy is the first option with an often
atisfactory response. In some cases, beta-blockers should be
ombined with high thoracic left sympathectomy (38).
hen still ineffective, pacemaker implantation to ensure
table heart rates may be necessary. If risk remains, implan-
ation of an implantable cardioverter-defibrillator (ICD) is
arranted. This should always be combined with beta-
lockers, as shock delivery is associated with a strong
drenergic stimulus. For LQT3 patients, ICD implantation
ombined with beta-blockers would be first-choice therapy
38,39).
HE BRUGADA SYNDROME
n 1992, Brugada et al. (41) described eight cases of aborted
CD in patients without demonstrable structural cardiac
isease and a peculiar ECG pattern consisting of (in)com-
lete right bundle branch block or elevated J point in
ssociation with ST-segment elevation in leads V1 to V3,
nd a normal QT interval. The ST segments in the right
recordial leads may either show an upward convex or a
o-called saddle-back–shaped contour. Often, left axis de-
iation is also present (42). Since the first publication (41),
ore reports emerged, suggesting a disorder more common
han previously assumed (42–45). At present, the diagnostic
riteria for the Brugada syndrome are not unequivocal. The
rerequisite is ST-segment elevation in the right precordial
eads, but no consensus exists about the required amount of
levation (1 mm or 2 mm). Furthermore, the ST-
egment abnormalities may have a dynamic character. They
ay be transient, at times even absent, or have a changing
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VF Without Structural Heart Disease April 7, 2004:1137–44xpression. The J-point elevation on the ECG may be
xaggerated, but is sometimes only discernible after admin-
stration of a sodium-channel blocking agent (gilurythmal,
ecainide, procainamide) (45). The J-point elevation may
e due to a more prominent epicardial manifestation of the
pike-and-dome action potential morphology, mediated by
transient outward potassium current (Ito) (45). Conditions
hat enhance Ito predispose the epicardium to regional
ll-or-none repolarization, resulting in dispersion of repo-
arization, which may lead to arrhythmias based on phase-2
e-entry. This phenomenon is most pronounced in the right
entricular free wall and outflow tract, which, therefore,
ave been suggested as the site of arrhythmia origin (41–
5). Symptomatic patients either present with VF (73%) or
yncope (27%) (44). However, individuals with a “Brugada”
CG may remain asymptomatic. Syncope and (aborted)
CD are specifically ascribed to the occurrence of rapid
olymorphic VT/VF. In some cases, conduction defects
uch as atrial standstill have been described (46). During
PS, a prolonged HV-interval is often found. In about 75%
f patients with the Brugada syndrome, polymorphic
T/VF is inducible (44). Monomorphic VTs (with left
undle branch morphology that seemed to originate in the
ight ventricle) occurring spontaneously and being inducible
t EPS are quite unusual (47).
The Brugada syndrome may be a heritable disease,
nvolving the SCN5A gene encoding the cardiac sodium-
hannel (43). Of interest, defects of the SCN5A gene are
ssociated with both LQT3, Brugada syndrome, and famil-
al conduction defects (familial Lene`gre’s disease) (48).
lso, the typical manifestations of LQT3 (QT prolonga-
ion) and Brugada syndrome (ST elevation in leads V1 to
3) may coexist in the same patients. Moreover, both
iseases have the following clinical features in common: 1)
uspected or certain lack of efficacy of beta-blockers; 2) high
ethality during cardiac events; and 3) arrhythmias occurring
t rest or sleep. These observations raise questions about the
ctual differences between LQT3 and the Brugada syn-
rome (40,46).
udden unexpected nocturnal death syndrome. Sudden
nexplained death, occurring at night (usually during sleep),
as been observed in apparently healthy Southeast Asian
ubjects (49–51). It is known under different names: ban-
ungut (rising and moaning during sleep), Philippines;
okkuri (sudden unexpected death), Japan; and laitai (sleep
eath), Laos. Annual prevalences of 1:2,500 inhabitants
Thailand) and 1:1,000 (Laos) have been reported (51).
vents are accompanied by night terrors and nocturnal
ocalizations. Debate exists concerning possible cause(s)
2,3). A toxic cause has been suspected. Some pathologic
xaminations reported cardiomegaly and abnormalities of
he specialized conduction tissue. Recent evidence suggests
hat the syndrome may, in fact, be an expression of the
rugada syndrome (51).
reatment. Consensus exists that symptomatic patientsulfilling the criteria of the Brugada syndrome should neceive an ICD (41–45). The same may apply to asymp-
omatic individuals who fulfill the ECG criteria of the
yndrome and have a (malignant) family history of SCD.
HORT-COUPLED TORSADE DE POINTES
n 1994, Leenhardt et al. (32) first described an entity of
orsades de pointes in patients without demonstrable struc-
ural heart disease and without QT prolongation on the
CG. In contrast with LQTS patients, torsades de pointes
ere initiated by extremely short-coupled ventricular extra-
ystoles. A family history of SCD may be present in up to
0%. The arrhythmia is observed in the context of a
articular profile of the autonomic nervous system with low
eart rate variability and high sympathetic to parasympa-
hetic ratio.
reatment. Class I antiarrhythmic drugs, beta-blockers,
nd amiodarone appeared ineffective. Verapamil seemed to
iminish the occurrence of torsades de pointes, but not the
ccurrence of SCD. Implantable cardioverter-defibrillator
mplantation seems the safest therapy.
ATECHOLAMINE-INDUCED POLYMORPHIC
ENTRICULAR TACHYARRHYTHMIA IN CHILDREN
erious ventricular tachyarrhythmia occurs rarely in chil-
ren. A clearly defined entity, apart from LQTS, the
rugada syndrome, and the short-coupled torsades de
ointes, is that of the so-called catecholaminergic polymor-
hic VT in childhood and adolescence. In 1975, Coumel et
l. (52) first described four cases of severe ventricular
rrhythmias in children with normal QT intervals. Ventric-
lar tachycardia/ventricular fibrillation are reproducibly pro-
oked by any form of sympathetic stimulation. Very re-
ently, it was demonstrated that mutations in the cardiac
yanodine receptor gene (hRyR2) are responsible (53).
reatment. Crucial is that these patients comply with
eta-blockers. Analogies may exist between catecholamine-
nduced polymorphic ventricular tachyarrhythmias and
QTS. Genetic research may be required for further clari-
cation. Implantable cardioverter-defibrillator treatment
ay become part of the therapy, although special attention
hould be given to the catecholaminergic influence of ICD
hock delivery. As in LQTS, ICDs should never be im-
lanted without concomitant beta-blockers.
DIOPATHIC VF
erminology. The remaining group of VF patients with-
ut identifiable structural heart disease is classified as having
diopathic VF. The syndrome has also been referred to as
rimary electrical disease (1), primary VF, or arrhythmic
eath without identifiable heart disease (3). These terms
ay be too broad or misleading. Therefore, idiopathic VF is
resently considered the best terminology to acknowledge
he current inability to identify a specific cause. This does
ot imply that a patient’s heart is completely free of any
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April 7, 2004:1137–44 VF Without Structural Heart Diseasetructural or functional abnormality, but merely that if an
bnormal finding (e.g., first-degree AV block or atrial
brillation) is present, it is not considered responsible for
he VF episode (3). Because idiopathic VF may not repre-
ent a homogeneous disease, future research may identify
pecific causes in certain subsets, as was the case for LQTS.
inor abnormalities. Current consensus is that some
inor abnormalities, unknown to be associated with the
ccurrence of VF, do not rule out the diagnosis. A com-
ined Task Force of the Unexplained Cardiac Arrest Reg-
stry of Europe (UCARE) and Idiopathic Ventricular
ibrillation Registry of the United States of America
IVF-US) (3) recently summarized a variety of minor
bnormalities that may be compatible with a diagnosis of
diopathic VF. These include nonspecific biopsy findings,
inor hemodynamic abnormalities, such as borderline right
nd left ventricular indexes, subtle wall motion abnormali-
ies, and isolated mitral valve prolapse without valve redun-
ancy, thickening, regurgitation, left ventricular dysfunc-
ion, QT prolongation or ST-T changes. There is general
greement that paroxysmal and chronic atrial fibrillation,
er se, have no specific relation to SCD in the absence of
PW or hyperthyroidism or in persons 70 years old.
ther findings not associated with SCD are first-degree AV
lock and temporary second-degree AV block (Wenckebach
ype) not associated with marked bradycardia, hypertension
ithout left ventricular hypertrophy, isolated modest thick-
ning of the interventricular septum or left ventricular free
all (10% of normal), and isolated bundle branch block.
ncidence. Sudden cardiac death in patients without major
nderlying disease occurs infrequently although, in larger
eferral centers, percentages varying from 1% to 14% were
eported (1); UCARE (3) reported a prevalence of about
%. These estimates indicate that VF with absent organic
eart disease may be more common than previously
ecognized.
ecurrence risk. Previously, prognosis was considered ex-
ellent (1,54). There appeared to be agreement that only
ymptomatic patients with recurrent arrhythmia should be
reated. No particular efforts were directed toward identifi-
ation of high-risk subgroups or SCD prevention. Data
rom several recent studies, however, suggest recurrence
ates of VF, syncope, or cardiac arrest varying from 25% to
3% over longer follow-up (1,3).
In the early 1990s, our center was the first to report
esults of a prospective study of patients with primary
lectrical disease who survived a VF episode (1). The major
nding of this study was the high recurrence rate of
ife-threatening events during long-term follow-up, in often
oung (40 years) patients.
Until 1999, 37 survivors of out-of-hospital cardiac arrest
ue to idiopathic VF were referred to our institute. Mean
ge was 35 (range, 13 to 73) years. There were 26 males and
1 females. Mean follow-up was 77  41 months. Total
ortality was 3 of 37 patients (8%); 16 of the 37 patients43%) had recurrent episodes of syncope, documented wentricular tachyarrhythmia, or SCD during follow-up.
igure 1 shows the Kaplan-Meier curve for survival free of
hese events. One patient died from a noncardiac cause after
30-month follow-up. Previously, he had received shocks
or documented VT/VF.
In our series, patients with (possible) ECG signs indic-
tive of the Brugada syndrome were not excluded. Retro-
pective analysis showed that nine of 37 patients (24%)
ould have been classified as having Brugada syndrome
ased on the presence of (in)complete right bundle branch
lock and1 mm ST elevation in the precordial leads V1 to
3. If the prerequisite amount of elevation would be 2
m in leads V1 to V3, 3 of the 37 patients (8%) would have
een classified as having Brugada syndrome. Recurrence
ate was 3 of 9 (33%) in the patients with 1 mm
T-segment elevation, 2 of 3 in the patients with 2 mm
T-segment elevation, and 13 of 28 (46%) in the remaining
atients.
Ergonovine testing was not performed routinely during
aseline analysis before 1992 (1,23). However, in 11 pa-
ients included before 1992 who had received an ICD,
rgonovine testing was done later, resulting in only one
ositive reaction. All together, positive ergonovine testing
ith completely normal coronary anatomy in our experience
s very rare in this patient subset (1,55).
reatment. In this subgroup, prognosis is mainly related to
he ability to control the electrophysiologic derangements.
dditional risk due to advanced myocardial disease is
bsent. Therefore, if the arrhythmic risk is controlled,
rognosis of these patients may be similar to that of
atched controls from the general population. Some au-
hors have reported favorable results with class I antiar-
hythmic agents guided by serial drug testing (56). How-
ver, in addition to uncertainties about long-term efficacy,
atient compliance to antiarrhythmic drugs remains a major
oncern. Even if an antiarrhythmic drug regimen would be
ffective, it is well known that many patients (25%) discon-
inue their drugs over time, either because of adverse effects
r due to negligence during event-free periods. Currently,
here is consensus that, in these patients, preventive therapy
igure 1. Kaplan-Meier curve showing survival free of major events
sudden death, recurrent episode of syncope, or documented ventricular
achyarrhythmia) of 37 consecutive patients with idiopathic ventricular
brillation admitted to our center between 1985 and 1999.ith antiarrhythmic drugs, including beta-blockers, is in-
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VF Without Structural Heart Disease April 7, 2004:1137–44ufficient and that ICD implantation is the safest and most
ffective secondary prevention therapy.
IAGNOSTIC EVALUATION
oninvasive evaluation. Idiopathic VF is a diagnosis by
xclusion. Therefore, this diagnosis can only be made when
horough clinical evaluation does not provide evidence for
tructural heart disease or other known causes of VT/VF. It
s recommended to perform an extensive evaluation using a
redefined protocol. Acute myocardial infarction must be
xcluded, as well as transient and correctable causes of
T/VF (acute myocardial ischemia, metabolic or electrolyte
isturbances, drug toxicity). After prolonged resuscitation
15 min), a transient period of ventricular dysfunction
ay ensue, lasting for 48 h or longer. Therefore, ventricular
unction assessment should not be performed too soon after
he index episode.
Baseline evaluation starts with a careful analysis of the
atient’s history, family history, use of drugs, complete
outine physical examination, laboratory testing, and chest
oentgenograms.
Laboratory testing should include serum measurement of
lectrolytes (potassium, calcium, magnesium), and thyroid
unction. Furthermore, analysis of possible drugs in the
erum should be performed. It may be worthwhile to save
ome serum for later investigations. Urine testing may
nclude vanillyl mandelic acid measurement and analysis of
rug toxicity (3).
Electrocardiographic analysis includes (repeated) 12-lead
CGs, 24- to 48-h Holter monitoring, exercise testing,
nalysis of the response to the Valsalva maneuver (57), and
rousal. Preexcitation and long QT interval patterns, either
ersistent or transient, must be excluded. To enable thor-
ugh analysis, it is mandatory that patients stay on telemetry
onitoring during hospitalization. Further analysis may
nclude signal-averaged ECG and measurement of heart
ate variability and baroreflex sensitivity.
maging techniques. Echocardiography and Doppler
creening must be performed to analyze ventricular wall
otion and valvular function at appropriate timing after the
ndex event. Contrast echocardiography may additionally be
erformed. Nuclear scintigraphic evaluation comprises as-
essment of left and right ventricular ejection fraction, and
nalysis of myocardial perfusion. Magnetic resonance imag-
ng or positron emission tomography scanning may be of
elp to establish the diagnosis in patients with otherwise
on-overt right ventricular cardiomyopathy or other con-
enital abnormality.
nvasive evaluation. Left and right heart catheterization
ust be performed including measurement of pressures and
xygen saturations (in the superior and inferior caval veins,
ight atrium, both ventricles, pulmonary artery and pulmo-
ary wedge position, and thoracic aorta). Catheterization
ust include cineangiography of both ventricles and coro-ary angiography. Testing for coronary artery spasm should oarticularly be considered in the presence of hemodynami-
ally insignificant coronary artery lesions (23). Myocardial
ridging would lead to exclusion of the diagnosis of idio-
athic VF only when accompanied by evidence of myocar-
ial ischemia. Although not considered mandatory, multiple
iopsies may be taken from the right ventricular
ndomyocardium.
Baseline EPS should be performed off antiarrhythmic
rugs including analysis of sinus node recovery time and AV
onduction parameters (1). Programmed electrical stimula-
ion should be performed according to standard techniques
nd protocols, including burst pacing and—if necessary—
soproterenol infusion (1,58). End points of the procedure
re completion of programmed electrical stimulation proto-
ols or reproducible induction of VT/VF associated with
emodynamic collapse.
harmacologic testing. Ergonovine testing is advocated
ither during catheterization or at another stage under ECG
onitoring, once the coronary anatomy is known. Admin-
stration of gilurythmal, flecainide, or procainamide (45)
ay be done during EPS or at another stage under careful
CG monitoring. Of note is that administration of these
rugs in the presence of concealed Brugada syndrome may
lso provoke VT/VF.
enetic evaluation. Advances in molecular genetics have
hed new light on the mechanism of many disease states,
ncluding arrhythmias. Further progress may ultimately
reak down the enigma of idiopathic VF, much as it did so
n the LQTS. At present, however, genetic analysis is
ime-consuming, costly, and not widely available. It is,
herefore, not considered part of the routine diagnostic
rotocol. Moreover, other important questions need to be
ealt with: 1) which patients should undergo genetic eval-
ation; 2) is genetic evaluation of the patient’s relatives
ndicated; 3) what are the consequences of such investiga-
ions for the patients and their relatives; and 4) genetic
ounseling. Elaboration of these questions is beyond the
cope of this paper.
inimally required diagnostic tests. For exclusion of
nderlying structural heart disease, the Joint Steering Com-
ittees of UCARE and IVF-US have advocated the fol-
owing minimally required diagnostic tests: clinical history,
hysical examination, blood chemistry, ECG, exercise stress
est, 24-h Holter recording, echocardiography, coronary
ngiography, right and left ventricular cineangiography, and
PS (3). Other investigations are strongly recommended
ut not mandatory.
valuation during follow-up. A disease is called idio-
athic if present knowledge and investigational tools have
ot (yet) identified an underlying etiology. However, an
ndex episode with electrical instability may be the first
xpression of structural cardiac disease not yet detectable at
resent. Currently, the absence of structural abnormalities is
sually concluded from findings of relatively gross tests
cardiac catheterization, echocardiography). Possibly, devel-
pment of newer and more refined diagnostic techniques
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April 7, 2004:1137–44 VF Without Structural Heart Diseaseay change the situation. During follow-up, clinical reeval-
ation using noninvasive tests, such as ECG, Holter record-
ng, echocardiography, and, eventually, magnetic resonance
maging must be repeated at certain intervals (e.g., once a
ear) to assess whether abnormalities develop over time.
ummary. Sudden cardiac death occurs in 90% of cases
n persons with known or previously unrecognized structural
r functional cardiac abnormalities. Coronary artery disease
nd cardiomyopathies are the predominant underlying ab-
ormalities. A minority of patients does not show any
bnormality. Currently, several entities are recognized with-
ut structural heart disease but with distinct electrophysi-
logic abnormalities, including WPW syndrome, long QT
yndrome, Brugada syndrome, short-coupled torsade de
ointes, and catecholamine-induced polymorphic ventricu-
ar tachyarrhythmia (in children). In the remainder, some
%, no such abnormalities are identifiable. Such patients are
ategorized as having idiopathic VF. Mostly, this concerns
atients at a younger age (40 years). Possibly in the future,
ith development of newer diagnostic tools (magnetic
esonance imaging, positron emission tomography, genetic
esting), some or all cases of idiopathic SCD may have to be
edefined as having a specific genetic and/or anatomic basis.
All patients successfully resuscitated from VT/VF with-
ut clear precipitating factors (acute myocardial infarction
r severe electrolyte or metabolic disturbances) are at high
isk of recurrent events. Long-term preventive therapy is
ndicated. In contrast with earlier beliefs, survivors of
diopathic VF are now considered at high risk. In our
xperience, the recurrence rate of life-threatening episodes
as as high as 43% after lengthy follow-up (77  41
onths). Preliminary data of U-CARE suggest a 30%
ecurrence rate. The ICD is the safest and most effective
herapy.
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